news

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

12.16.2019

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

12.09.2019

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12.05.2019

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A

12.03.2019

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

12.02.2019

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11.27.2019

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

11.16.2019

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

11.07.2019

BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

10.22.2019

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

10.17.2019

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

10.14.2019

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

09.24.2019

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

09.09.2019

BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference

09.05.2019

BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) with new subsidiary ML Bio Solutions

09.05.2019

BridgeBio Pharma Announces Pricing of Its Initial Public Offering

06.26.2019

BridgeBio Pharma Announces Filing of Registration Statement for Proposed Initial Public Offering

05.24.2019

Eidos Therapeutics Initiates Attribute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

02.27.2019

Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

02.22.2019

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

01.23.2019

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter, and Facebook to keep up with all of the latest news.

news archive

icon icon